Literature DB >> 7484192

Factorial structure of the 17-item Hamilton Depression Rating Scale.

M P Fleck1, M F Poirier-Littre, J D Guelfi, M C Bourdel, H Loo.   

Abstract

The Hamilton Depression Rating Scale was applied to 60 depressed inpatients diagnosed using the Composite International Diagnostic Interview. The information to rate the scale was obtained with a semistructured interview to standardize the scale administration method. Items were factorized using principal components analysis with Varimax rotation. Three factors were obtained with the simulation method, accounting for 47% of variance. The first includes the core symptoms of depression. The symptoms of patients having an isolated mood disorder were compared with those having comorbidity with other diagnoses. The comorbidity did not affect the first factor but modified the second factor (anxiety) and the third factor (insomnia).

Entities:  

Mesh:

Year:  1995        PMID: 7484192     DOI: 10.1111/j.1600-0447.1995.tb09562.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  13 in total

1.  Assessing anxious features in depressed outpatients.

Authors:  Shawn M McClintock; Mustafa M Husain; Ira H Bernstein; Stephen R Wisniewski; Madhukar H Trivedi; David Morris; Jonathan Alpert; Diane Warden; James F Luther; Susan G Kornstein; Melanie M Biggs; Maurizio Fava; A John Rush
Journal:  Int J Methods Psychiatr Res       Date:  2011-11-04       Impact factor: 4.035

2.  Religious struggle and religious comfort in response to illness: health outcomes among stem cell transplant patients.

Authors:  Allen C Sherman; Stephanie Simonton; Umaira Latif; Rebecca Spohn; Guido Tricot
Journal:  J Behav Med       Date:  2005-08

3.  A double-blind pilot dosing study of low field magnetic stimulation (LFMS) for treatment-resistant depression (TRD).

Authors:  Marc J Dubin; Irena P Ilieva; Zhi-De Deng; Jeena Thomas; Ashly Cochran; Kamilla Kravets; Benjamin D Brody; Paul J Christos; James H Kocsis; Conor Liston; Faith M Gunning
Journal:  J Affect Disord       Date:  2019-02-14       Impact factor: 4.839

4.  A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation.

Authors:  Michele Fornaro; Davide Prestia; Salvatore Colicchio; Giulio Perugi
Journal:  Curr Neuropharmacol       Date:  2010-09       Impact factor: 7.363

5.  The effect of interpersonal psychotherapy for depression on insomnia symptoms in a cohort of women with sexual abuse histories.

Authors:  Wilfred R Pigeon; Pamela E May; Michael L Perlis; Erin A Ward; Naiji Lu; Nancy L Talbot
Journal:  J Trauma Stress       Date:  2009-12

6.  Predictors for self-directed aggression in Italian prisoners include externalizing behaviors, childhood trauma and the serotonin transporter gene polymorphism 5-HTTLPR.

Authors:  E Gorodetsky; V Carli; M Sarchiapone; A Roy; D Goldman; M-A Enoch
Journal:  Genes Brain Behav       Date:  2016-05-05       Impact factor: 3.449

7.  The Effect of Sleep Disturbances on Major Depressive Disorder.

Authors:  Wilfred R Pigeon
Journal:  Depress Mind Body       Date:  2009

8.  Depressive Symptom Dimensions in Treatment-Resistant Major Depression and Their Modulation With Electroconvulsive Therapy.

Authors:  Benjamin S C Wade; Gerhard Hellemann; Randall T Espinoza; Roger P Woods; Shantanu H Joshi; Ronny Redlich; Anders Jørgensen; Christopher C Abbott; Ketil J Oedegaard; Shawn M McClintock; Leif Oltedal; Katherine L Narr
Journal:  J ECT       Date:  2020-06       Impact factor: 3.692

9.  Simultaneous Decomposition of Depression Heterogeneity on the Person-, Symptom- and Time-Level: The Use of Three-Mode Principal Component Analysis.

Authors:  Rei Monden; Klaas J Wardenaar; Alwin Stegeman; Henk Jan Conradi; Peter de Jonge
Journal:  PLoS One       Date:  2015-07-15       Impact factor: 3.240

Review 10.  Data-driven subtypes of major depressive disorder: a systematic review.

Authors:  Hanna M van Loo; Peter de Jonge; Jan-Willem Romeijn; Ronald C Kessler; Robert A Schoevers
Journal:  BMC Med       Date:  2012-12-04       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.